secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027463
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus completes first Decoy20 cohort; starts second cohort
-------------------------------------------------------------

- Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.
- Other adverse events (chills, fatigue, vomiting, fever) were grade 1-2 and resolved quickly.
- Immune activation observed via transient expression of cytokines/chemokines associated with innate and adaptive pathways.
- Second cohort initiated after Safety Review Committee review per protocol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/0001493152-23-027463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer